Wall Street analyst estimates for Damora Therapeutics, Inc. (GLTO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-05 | $-0.45 | ||
| 2026-03-18 | $-3.24 | $-0.14 | -2216.3% |
| 2025-11-06 | $-2.36 | ||
| 2025-08-05 | $-2.60 | ||
| 2025-05-08 | $-1.92 | ||
| 2025-03-19 | $-5.22 | $-3.12 | -67.3% |
| 2024-11-01 | $-3.39 | $-3.70 | +8.4% |
| 2024-08-12 | $-4.00 | $-8.00 | +50.0% |
Valuation Ratios
| Price / Book | 0.68 |
| EV / EBITDA | 1.90 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $111000 | 0 | 0 | 0 | 0 | 0 | $34000 |
| Gross Profit | 0 | -$111000 | 0 | 0 | 0 | 0 | 0 | -$34000 |
| Research & Development | $10.1M | $36.5M | $24.6M | $38.5M | $48.2M | $23.8M | $10.8M | $201.2M |
| Selling, General & Admin | $2.8M | $2.4M | $9.0M | $13.7M | $13.0M | $12.7M | $10.5M | $9.7M |
| Operating Expenses | $12.9M | $39.0M | $33.6M | $52.2M | $61.2M | $39.9M | $22.3M | $210.9M |
| Operating Income | -$12.9M | -$39.0M | -$33.6M | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$210.9M |
| EBITDA | -$12.9M | -$36.4M | -$34.6M | -$51.3M | -$60.7M | -$35.6M | -$21.1M | -$209.8M |
| Interest Expense | $3.0M | 0 | 0 | 0 | $417000 | 0 | 0 | 0 |
| Pre-tax Income | -$15.9M | -$36.5M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | $41000 | $50000 |
| Net Income | -$15.9M | -$38.4M | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| EPS | $-4.42 | $-37.76 | $-35.66 | $-50.75 | $-61.04 | $-36.08 | $-18.53 | $-152.99 |
| EPS (Diluted) | $-4.42 | $-37.76 | $-35.66 | $-50.75 | $-61.04 | $-36.08 | $-18.53 | $-152.99 |
| Shares Outstanding (Diluted) | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.1M | $1.2M | $1.4M |
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks